AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05071092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counselling
Description: Participants assigned to the intervention group will receive coaching from a dietitian to improve adherence to the Dutch dietary guidelines. Several behavioral change techniques will be used.
Study NCT05130411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DLM - Test product
Description: The group will receive 60 gummies each (to take two gummies per day) across a four-week period. Each participant shall take two gummies per day
Study NCT05268861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Error Augmentation Feedback
Description: Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. Subjects will receive an elbow flexion error of 15 degrees to encourage elbow extension.
Study NCT05268861 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No Error Augmentation Feedback
Description: Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. In this case, subjects that do not receive EA feedback will act as sham comparators.
Study NCT04747470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered as an IV infusion
Study NCT04747470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered as an IV infusion
Study NCT04747470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered as an IV infusion
Study NCT04747470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Administered as an IV infusion
Study NCT04747470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered as an IV infusion
Study NCT04763629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Patients of both arms will undergo two different modalities of exercise during the 12 weeks study period.
Study NCT06189482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oral-esophageal Tube Feeding
Description: During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The observation group receives IOE for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2, as shown in the Appendix), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
Study NCT06189482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasogastric tube feeding
Description: During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The control group is provided with nutritional support as NGT, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
Study NCT05708456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application with symptom management
Description: In this study, patients will be given evidence-based advice via a mobile application to manage their symptoms.
Study NCT04776512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP Block With Bupivacain
Description: bilateral lumbar ESP block using 0.375% Bupivacain
Study NCT04776512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Analgesia
Description: Continuous Lumbar Epidural analgesia With 0,125% Bupivacain+0,25 mcg/ml Sufentanil
Study NCT06298786 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Functional 6-minute mastication test
Description: All participants will be evaluated in 3 different phases. First, they will respond to the online TMD screener questionnaire. Then, they will be presentally evaluated using the DC/TMD and finally they will undergo the functional 6-minute mastication test.
Study NCT02633514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2,iv gtt,d1-3
Study NCT02633514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 75mg/m2,iv gtt,d1-3
Study NCT02633514 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 60Gy/30Fx
Study NCT02633514 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: radiotherapy
Description: 60Gy/30Fx
Study NCT04869826 — intervention group
Intervention type: DEVICE
Intervention: Pulsewave Health Monitor (PAD-2A) Device
Description: This is an observational, comparison study of blood pressure measurements. The objective of this study is to calibrate the blood pressure measurements of the Pulsewave Health Monitor (PAD-2A) device to be within 5±8 mmHg of the average of the dual-observer auscultatory blood pressure measurements via an aneroid sphygmomanometer (reference device), as per the ISO 81060-2: AMD_2020 universal protocol.
Study NCT06166615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Ramosetron (a 5-HT3 receptor antagonist) has been developed as an effective treatment for irritable bowel syndrome-diarrhea (IBD-D) and is used to decrease intestinal motility, stiffen stool consistency, and reduce the number of urgency bowel movements. Since one of the goals of treatment for fecal incontinence is the maintenance of stool consistency, this agent is expected to be effective in treating fecal incontinence.
Study NCT06166615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium
Description: Psyllium was found to be the most effective at improving symptoms of fecal incontinence among several dietary fibers in a randomized, controlled, single-blind study and is currently used as a first-line treatment for fecal incontinence.
Study NCT04889638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cessation Intervention
Description: 1. Pharmacotherapy selection, prescription and monitoring of up to two types of cessation pharmacotherapies: Nicotine replacement therapy (gum, lozenge and transdermal patch) and non-nicotine replacement therapy (varenicline).~2. Remote video-conferencing and mobile phone-based, personalized motivational messaging
Study NCT04793217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving AIDS Care After Trauma +
Description: ImpACT+ integrates skills for HIV treatment adherence and coping with trauma, tailored to the South African context. This includes exploration of values informing care engagement, recognizing the synergistic stress of sexual trauma and HIV, understanding the contribution of stressors to maladaptive coping, and developing adaptive methods for coping as alternatives to avoidance. ImpACT+ will be delivered in private spaces at the primary care clinic and will consist of 6 individual sessions followed by 6 maintenance check-ins. Individual sessions focus on coping, adherence, and care engagement during an early critical period, while maintenance check-ins reinforce positive change and support ongoing implementation of skills. Evidence supports a 6-session format in low-resource settings. Individual sessions will begin within 2 weeks after the baseline survey and be completed by the 4-month assessment. Maintenance check-ins will begin following the 4-month assessment.
Study NCT04793217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Problem-Solving Therapy
Description: Participants will receive three weekly individual sessions of adapted PST. The goal of PST is to identify problems that interfere with daily activities and address them through problem-orientation work. We anticipate stressors will include (a) relationship difficulties, including family stress, (b) financial stress and unemployment, (c) general impact of HIV infection, and (d) overall chronic stress. Thus, PST may indirectly address stressors that may impact care engagement, but will not address the intersection of HIV and trauma specifically.
Study NCT01184157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home screening
Study NCT01184157 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic screening
Study NCT06079112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: 1.0/1.25/1.5 mg/kg, intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
Study NCT06079112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
Study NCT05044806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided remote ischemic conditioning
Description: Before conducting RIC, Doppler ultrasound was used to measure the total occlusion pressure (TOP) of brachial artery, which was then determined as the cuff inflation pressure during RIC. The RIC program encompasses four main components of (1) three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2) one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3) three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of RIC with 3 min intervals of reperfusion in between, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning.
Study NCT05044806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional remote ischemic conditioning
Description: The RIC program encompasses four main components of (1)three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2)one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3)three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of upper limb ischemia on the arm that is opposite to the PCI side with 3 min intervals of reperfusion in between delivered by an automated cuff inflation/deflation device, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning. The pressure applied during cuff inflation is 20 mmHg above systolic blood pressure.
Study NCT06231849 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: stool analysis
Description: stool analysis to determine number of gut microbiota in subjects with opioid use and its effect on its intoxication.
Study NCT05044806 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI) will be performed by a cardiologist or doctor who specializes in the heart to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI requires cardiac catheterization, which is the insertion of a catheter tube, and live x rays helping to guide the catheter into the heart to inject special contrast dye that will highlight the blockage. To open a blocked artery, another catheter will be inserted over a guidewire, a balloon will be inflated at the tip of that catheter, and a small mesh tube called a stent may be put in the artery to help keep the artery open. After PCI, the catheters will be removed, the opening on the wrist or groin will be closed and bandaged.
Study NCT05044806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI) will be performed by a cardiologist or doctor who specializes in the heart to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI requires cardiac catheterization, which is the insertion of a catheter tube, and live x rays helping to guide the catheter into the heart to inject special contrast dye that will highlight the blockage. To open a blocked artery, another catheter will be inserted over a guidewire, a balloon will be inflated at the tip of that catheter, and a small mesh tube called a stent may be put in the artery to help keep the artery open. After PCI, the catheters will be removed, the opening on the wrist or groin will be closed and bandaged.
Study NCT05147896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Oral Tablet
Description: Semaglutide Oral Tablets will be introduced to the active arm as per protocol for regular therapy introduction.
Study NCT05732025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrohydraulic shock wave lithotripsy
Description: Pre-treatment of severe calcified coronary lesions with electrohydraulic shock wave lithotripsy
Study NCT05732025 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotary atherectomy
Description: Pre-treatment of severe calcified coronary lesions with rotary atherectomy
Study NCT06042556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IUD self-removal guide
Description: We previously developed an online guide for IUD self-removal through an iterative process including advice from key expert informants, focus groups, interviews, and a pilot clinical study. It includes an online animation, step-by-step guide, troubleshooting tips, and information about pregnancy and contraception.
Study NCT00935675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10 mg once a day
Study NCT00935675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10 mg once a day
Study NCT04961190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: A form of cognitive-behavioral psychotherapy focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
Study NCT04961190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacotherapy with paroxetine or venlafaxine XR
Description: Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a serotonin-norepinephrine reuptake inhibitor that is FDA approved to treat anxiety and depression
Study NCT06722469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WCI
Description: The WCI group will receive automated messages based on the Health Belief Model (HBM) and Protection Motivation Theory (PMT), including personalized risk assessments, educational videos featuring medical professionals and relatable scenarios, and tailored prompts to encourage mammographic screening.
Study NCT06722118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone IV
Description: IV-DXM 4mg/ml, injectable solution. Dosage of 0.25 mg/kg (maximum 5 mg per dose), prepared in a syringe of 5 to 10 ml and administered intravenously to the patient over 10 minutes every 6 hours. The treatment duration ranges from 6 hours (minimum of two doses: H0, H6) to 18 hours (maximum of four doses: H0, H6, H12, H18).
Study NCT06722118 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 0.9% NaCl solution, prepared in a syringe of 5 to 10 ml and administered intravenously to the patient over 10 minutes every 6 hours. The treatment duration ranges from 6 hours (minimum of two doses: H0, H6) to 18 hours (maximum of four doses: H0, H6, H12, H18).
Study NCT06723093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Medicine Housing Initiative
Description: Through the Social Medicine Housing Initiative, patients will receive access to permanent supportive housing and support services based on a social medicine model. The Housing Initiative provides a housing-first approach which offers housing to individuals without prerequisites (e.g., requiring cessation of substance use, adherence to treatment). Housing will be provided through a rent-geared-to-income model, with participants paying up to 30 percent of their income towards rent.~Participants will also be provided with customized social and medical support within and beyond the University Health Network, tailored to their specific needs and preferences. Patient care will be a collaborative effort involving the housing provider, the Social Medicine team, and community agencies.
Study NCT06722911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 400 mg on Day 1 and 15 of a 28-day cycle (6 cycles) ; Patients will receive Nimotuzumab 600 mg on days 1 and 8 of every 21-day cycle. Patients will receive six treatment cycles unless there is radiologic evidence of disease recurrence and unacceptable toxicity.
Study NCT06722911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG
Description: Patients will receive nab-paclitaxel 125 mg/m\^2 followed by gemcitabine 1,000 mg/m\^2 as one intravenous infusion over 30-40 minutes on days 1 and 8 of every 21-day cycle. Patients will receive six treatment cycles unless there is radiologic evidence of disease recurrence and unacceptable toxicity.
Study NCT06723548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Patients with MG who fulfill the inclusion criteria will receive Telitacicept 240mg weekly as an adjunct to their medication. Upon reaching MMS, significant symptom improvement, or a QMG score reduction of at least 6 points, Telitacicept is reduced to biweekly doses. Pyridostigmine and NSISTs are tapered based on patient response. Following this, Prednisone is tapered, starting with rapid reduction early and slowing later. If a patient on 60mg Prednisone daily achieves treatment goals within 6-8 weeks of Telitacicept initiation, the tapering sequence is 60mg every other day for 4 weeks, then 30mg daily for 2-4 weeks, and so on, until reaching 5mg daily or 10mg every other day. At this point, Telitacicept may be reduced to 160mg biweekly.
Study NCT06722716 — intervention group
Intervention type: OTHER
Intervention: Swab collection
Description: Nasopharyngeal swab
Study NCT06724250 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback therapy
Description: Biofeedback therapy involves the use of specialized equipment to provide real-time feedback on pelvic floor muscle activity. Participants are trained to improve muscle coordination and relaxation through guided exercises, targeting the resolution of dyssynergic defecation.
Study NCT06724250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A (Botox )
Description: Botulinum toxin is injected into the pelvic floor muscles to reduce muscle overactivity and improve coordination, aiming to relieve symptoms of dyssynergic defecation.
Study NCT06724796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Y4BI
Description: The yoga classes will follow the Iyengar method, one of the most widely practiced traditional yoga styles, aimed at promoting body alignment and precision in executing poses (asanas) through the use of props such as blankets, straps, cushions, chairs, and blocks, making the poses accessible to all individuals.~The classes will be conducted once a week, in groups, with each session lasting 1 hour. They will be led by a qualified instructor with over 10 years of teaching experience in yoga. The classes will be adapted for beginners who do not practice yoga regularly.
Study NCT06724796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVE
Description: The total body classes will take place once a week, with each session lasting one hour. They will be led by a kinesiology specialist in preventive and adapted physical activities.
Study NCT06723496 — intervention group
Intervention type: BEHAVIORAL
Intervention: Child Behavioral Checklist (CBCL):is a checklist parents complete to detect emotional and behavioral problems in children and adolescent, it consists of 113 questions for both groups.
Description: is a checklist parents complete to detect emotional and behavioral problems in children and adolescent, it consists of 113 questions.
Study NCT06723496 — intervention group
Intervention type: BEHAVIORAL
Intervention: parent report on child's responses to stress (PCT):is a questionnaire which is used to obtain mothers' and fathers' reports of their children's coping with cancer
Description: It includes a list of 12 cancer -related stressors (e.g., missing school, frequent hospital or clinic visits, changes in personal appearance), and 57 items reflecting voluntary (coping) and involuntary (automatic) stress responses of children /adolescents in response to cancer-related stressors